Jason Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the promising combination of a PD-1 antibody plus an IDO inhibitor for the treatment of patients with melanoma.<br />
Jason Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the promising combination of a PD-1 antibody plus an IDO inhibitor for the treatment of patients with melanoma.
Management of Immune-Related Toxicities in Melanoma Has Improved Over Time
April 24th 2024During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
Read More